Application of recombinant protein FSTL1 in preparation of medicine for treating osteoarthritis
Through the anti-inflammatory and immune regulatory properties of the recombinant protein FSTL1, the secretion of inflammatory factors and the restoration of chondrocyte expression is solved, and the problem that the existing technology cannot effectively treat osteoarthritis is achieved, and the effect of inhibiting degenerative cartilage lesions and delaying joint degeneration is achieved. .
Patent Information
- Application Number
- CN202411266952.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-03
AI Technical Summary
Existing pharmacological methods cannot effectively delay or treat the course of osteoarthritis, especially degenerative cartilage lesions.
Using the recombinant protein FSTL1, through its anti-inflammatory and immune regulatory properties, it inhibits the secretion of inflammatory factors of MMP13, IL-1α, IL-1β, TNF-α, and HMGB1, restores the expression of COL 2 in chondrocytes, and prepares it for injection treatment. Osteoarthritis medication.
Effectively inhibit degenerative cartilage lesions, restore normal gait, improve pain threshold, delay articular cartilage degeneration, and is highly biologically active, safe and effective.
Smart Images

Figure CN119055747A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a recombinant protein and application thereof, and in particular to application of a recombinant protein FSTL1 in preparing a drug for treating osteoarthritis. Background Art
[0002] FSTL1, Follistatin-like 1, is a pro-inflammatory factor first discovered in the blood. Chronic degenerative diseases caused by an aging population are a huge challenge that the world must face. Among the many chronic diseases of the elderly, osteoarthritis (OA), including ankle osteoarthritis (AOA), is a joint degenerative disease that seriously affects the quality of life of the elderly, and current pharmacological methods cannot delay its course.
[0003] CN112175078A discloses a neutralizing antibody of follistatin-like protein 1 and its application, which uses the characteristics of neutralizing antibodies to offset the effects of FSTL1 and exerts an anti-rheumatoid arthritis effect. CN109633145A discloses a research method for using follistatin-like protein-1 in serum to assist in the assessment of early rheumatoid arthritis, and applies follistatin-like protein-1 in serum to diagnose early rheumatoid arthritis. It is urgent to study the application of recombinant protein FSTL1 in the preparation of drugs for the treatment of osteoarthritis, so as to play a role in the treatment and delay of osteoarthritis. Summary of the invention
[0004] In view of the above problems, the purpose of the present invention is to provide an application of a recombinant protein FSTL1 in the preparation of a drug for treating osteoarthritis. The drug for treating osteoarthritis provided by the present invention has the functions of restoring normal gait and improving pain threshold, restoring the expression of chondrocyte COL 2, inhibiting the secretion of inflammatory factors such as MMP13, IL-1α, IL-1β, TNF-α, and HMGB1, and delaying the degeneration of articular cartilage. At the same time, it has the characteristics of high biological activity, safety and effectiveness, and can effectively inhibit cartilage degenerative lesions.
[0005] In order to achieve the above object, the technical solution of the present invention is achieved as follows:
[0006] A use of a recombinant protein FSTL1 in preparing a drug for treating osteoarthritis, wherein the amino acid sequence of the recombinant protein FSTL1 is shown in SEQ ID NO.1.
[0007] Preferably, the drug for treating osteoarthritis prepared by the recombinant protein comprises the recombinant protein FSTL1 and a pharmaceutically acceptable carrier.
[0008] Preferably, the recombinant protein FSTL1 is of mouse species, expressed by a HEK293 system with a C-6*His tag, has a total length of 288 amino acids, and a molecular weight of 41-58 kDa.
[0009] Preferably, the pharmaceutically acceptable carrier is PBS.
[0010] Preferably, the drug for treating osteoarthritis is an injectable preparation.
[0011] Preferably, the osteoarthritis comprises cartilage degeneration.
[0012] Compared with the prior art, the present invention has the following beneficial effects:
[0013] The present invention utilizes the anti-inflammatory and immunomodulatory properties of recombinant FSTL1 to exert its anti-osteoarthritis effect, so that the prepared drug for treating osteoarthritis can effectively inhibit cartilage degeneration, further laying a foundation for treating osteoarthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a schematic diagram of the structure of the recombinant protein FSTL1 having the characteristics of signal, chain, disulfide bond, glycosylation, and modified residues according to Example 1 of the present invention;
[0015] Figure 2 This is a picture showing that FSTL1 effectively inhibits OA cartilage degeneration observed by HE staining in Example 1 of the present invention;
[0016] Figure 3 This is a diagram showing that FSTL1 effectively inhibits OA cartilage degeneration observed by safranin fast green staining in an example of the present invention;
[0017] Figure 4 The representative pictures and average blot area statistics of the mouse hind paw inkblot test in the present invention are shown, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ***: P<0.001, **: P<0.01, two-way ANOVA;
[0018] Figure 5 This is a statistical diagram of the average footprint distance of the mouse hind paw ink mark test in the embodiment of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ***: P<0.001, **: P<0.01;
[0019] Figure 6This is a graph of the 50% withdrawal threshold of the mouse hind paw acupuncture test in the embodiment of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ****: P<0.0001, two-way ANOVA;
[0020] Figure 7 This is a graph of the withdrawal delay of the hind paw acupuncture test in mice in the embodiment of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, *: P<0.05, two-way ANOVA;
[0021] Figure 8 The representative pictures of COL2 immunohistochemical staining of the knee joint of mice in the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ****: P<0.0001, *: P<0.05, two-way ANOVA, scale bar: 50 μm;
[0022] Fig. 9 The representative pictures of MMP13 immunohistochemical staining of the knee joint of mice in Example 1 of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, **: P<0.01, *: P<0.05, two-way ANOVA, scale bar: 50 μm;
[0023] Fig.10 The representative pictures of IL-1α immunofluorescence staining of the knee joint of mice in Example 1 of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ***: P<0.001, **: P<0.01, two-way ANOVA, scale bar: 20 μm;
[0024] Fig.11 The representative pictures of IL-1β immunofluorescence staining of the knee joint of mice in Example 1 of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ***: P<0.001, *: P<0.05, two-way ANOVA, scale bar: 20 μm;
[0025] Fig.12 The representative pictures of MMP13 immunohistochemical staining of the knee joint of mice in Example 1 of the present invention, wherein CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, **: P<0.01, *: P<0.05, two-way ANOVA, scale bar: 50 μm;
[0026] Fig.13 These are representative images of HMGB1 immunofluorescence staining of mouse knee joints in Example 1 of the present invention, CTRL: control group, OA: osteoarthritis group, Veh: solvent treatment, FSTL1: FSTL1 recombinant protein treatment, mean±SD, n=3, ***: P<0.001, *: P<0.05, two-way ANOVA, scale bar: 20 μm. DETAILED DESCRIPTION
[0027] In order to make the purpose, method and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0028] The present invention will be further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments.
[0029] A use of a recombinant protein FSTL1 in preparing a drug for treating osteoarthritis, wherein the amino acid sequence of the recombinant protein FSTL1 is shown in SEQ ID NO.1.
[0030] In a specific implementation process, the drug for treating osteoarthritis prepared by the recombinant protein comprises the recombinant protein FSTL1 and a pharmaceutically acceptable carrier.
[0031] In a specific implementation process, the recombinant protein FSTL1 is of mouse species and is expressed by a HEK293 system with a C-6*His tag, with a total length of 288 amino acids and a molecular weight of 41-58 kDa.
[0032] In a specific implementation process, the pharmaceutically acceptable carrier is PBS.
[0033] In a specific implementation process, the drug for treating osteoarthritis is an injectable preparation.
[0034] In a specific implementation, the osteoarthritis includes cartilage degeneration.
[0035] The following are specific embodiments
[0036] The embodiment of the present invention provides an application of a recombinant protein FSTL1 in preparing a drug for treating osteoarthritis, wherein the amino acid sequence of the recombinant protein FSTL1 is shown in SEQ ID NO. 1. The drug for treating osteoarthritis prepared by the recombinant protein comprises the recombinant protein FSTL1 and a pharmaceutically acceptable carrier.
[0037] Furthermore, the recombinant protein species is mouse, expressed by HEK293 system with C-6*His tag, with a total length of 288 amino acids and a molecular weight of 41-58 kDa. The schematic diagram of the FSTL1 protein structure with signal, chain, disulfide bond, glycosylation, and modified residue features is shown in Figure 1 shown.
[0038] Experimental process:
[0039] According to the average weight of each mouse (about 20 g), the final concentration of the recombinant FSTL1 protein was adjusted to 1 μg / 10 μl / vial according to the mouse weight, diluted with PBS and stored at -20°C.
[0040] The OA cartilage mouse model was established by meniscus rupture for 2 months. The control group was injected with PBS into the joint cavity, while the experimental group was injected with recombinant FSTL1 once a week for 2 months.
[0041] HE staining showed that FSTL1 effectively inhibited OA cartilage degeneration. Figure 2 , showing that intra-articular injection of recombinant FSTL1 can effectively inhibit cartilage degeneration, and the Mankin score of OA chondrocytes in the FSTL1 injection group (the higher the score, the better the cartilage) was significantly restored, and the Krenn score (the higher the score, the higher the degree of inflammation) was significantly decreased.
[0042] The results of the hind paw inkblot test showed that the inkblot area of OA mice injected with FSTL1 recombinant protein was significantly increased compared with that of OA mice injected with solvent. Figure 3 Safranin fast green staining showed that FSTL1 effectively inhibited OA cartilage degeneration. Figure 3 A: Red-fast green staining was used to detect the effect of supplementation of recombinant FSTL1 on the articular cavity cartilage of mice. The OA cartilage mouse model was established by anterior cruciate ligament rupture, and recombinant FSTL1 (1 μg / mouse) was supplemented at the same time. The control group was injected with an equal amount of dilution (PBS) once a week for 2 consecutive months, and the samples were fixed and stained; the middle column is the cartilage in the non-weight-bearing area, and the right column is the screenshot of the cartilage in the weight-bearing area, the scale bar is 200 μm (whole bone), 50 μm screenshot; Figure 3 B: Mankin score statistics, the higher the score, the better the cartilage; Figure 3 C: Krenn score statistics chart. The higher the score, the more significant the degree of inflammation.
[0043] The inkblot test of mouse hind paws showed that the distance between the hind paws was significantly shortened. Figure 4 , Representative images of the inkblot test on the hind paw of mice and statistics of the average inkblot area.
[0044] The results of the hind paw withdrawal test showed that the 50% hind paw withdrawal threshold of OA mice injected with FSTL1 recombinant protein was significantly higher than that of OA mice injected with solvent. Figure 5 shown.
[0045] Hind paw withdrawal latency was significantly prolonged, as Figure 6 Shown are the 50% withdrawal threshold of the mouse hind paw test.
[0046] The mouse hind paw needle prick test withdrawal delay Figure 7 shown.
[0047] Furthermore, after IHC staining of the knee joints, the results showed that the COL2 content in the articular cartilage of OA mice injected with FSTL1 recombinant protein was significantly higher than that of OA mice injected with solvent, such as Figure 8 As shown in Figure 2, the levels of MMP13, IL-1α, IL-1β, TNF-α, and HMGB1 were significantly lower. Figure 9-13 shown.
[0048] In summary, the present invention utilizes the anti-inflammatory and immunomodulatory properties of recombinant FSTL1 to exert its anti-osteoarthritis effect, so that the prepared drug for treating osteoarthritis can effectively inhibit cartilage degeneration, further laying a foundation for the treatment of osteoarthritis.
[0049] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any method personnel familiar with the field of the method can easily think of changes or substitutions within the scope of the method disclosed in the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. Use of a recombinant protein FSTL1 in the preparation of a drug for treating osteoarthritis, It is characterized in that The amino acid sequence of the recombinant protein FSTL1 is shown in SEQ ID NO.
1.
2. The use according to claim 1, It is characterized in that The osteoarthritis treatment drug prepared by the recombinant protein comprises the recombinant protein FSTL1 and a pharmaceutically acceptable carrier.
3. The use according to claim 2, It is characterized in that The recombinant protein FSTL1 is of mouse species and is expressed by a HEK293 system with a C-6*His tag. It has a total length of 288 amino acids and a molecular weight of 41-58 kDa.
4. The use according to claim 3, It is characterized in that The pharmaceutically acceptable carrier is PBS.
5. The use according to claim 4, It is characterized in that The medicine for treating osteoarthritis is an injection preparation.
6. Use of the recombinant protein FSTL1 according to any one of claims 1 to 5 in the preparation of a drug for treating osteoarthritis, It is characterized in that The osteoarthritis includes cartilage degeneration.
Citation Information
Patent Citations
Research method for auxiliary evaluation on early-stage rheumatoid arthritis by using follistatin like protein-1 in serum
CN109633145A
Neutralizing antibody of follistatin-like 1 and application thereof
CN112175078A
